Flash Finance

Choksi Asia Ltd530427Corporate

Medical Equipment & Supplies Latest results: Jun 2026 14 quarters of data
₹235.20
MCap ₹122 Cr · P/E 23.5
Choksi Asia Ltd — Stock analysis & AI research Choksi Asia Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹9 Cr
Sales · Jun 2026
-22.5% YoY
₹1 Cr
Operating Profit · Jun 2026
-0.8% YoY
14.9%
OPM % · Jun 2026
+27.4% YoY
₹1 Cr
Net Profit · Jun 2026
-10.1% YoY
₹1.69
EPS · Jun 2026
-10.1% YoY

📝 Choksi Asia Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

Choksi Asia Ltd reported revenue of ₹9 crore for the quarter ended June 2026 (Q1 FY27), down 22.5% from ₹12 crore in the same quarter last year, and down 22.3% sequentially over the March 2026 quarter.

Net profit fell 10.1% year-on-year to ₹1 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹1.69.

Operating profit stood at ₹1 crore — an operating margin (OPM) of 14.9%, compared with 11.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Choksi Asia Ltd posted revenue of ₹49 crore, a growth of 61.1% over FY25, with a net profit of ₹5 crore (up 173.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹47 crore with a net profit of ₹5 crore.

Valuation snapshot

At the current price of ₹235.20, 530427 has a market capitalisation of ₹122 crore and a trailing P/E of about 23.5.

Within the Medical Equipment & Supplies industry, it is the 8th-largest of the 13 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 71.15%, foreign institutional investors (FIIs) 0.18%, public shareholders 28.67% of Choksi Asia Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹122 Cr
Current Price ?
₹235.2
P/E ?
23.50below ind
Industry P/E ?
26.90
P/B ?
2.90
P/S ?
2.62
P/FCF ?
-348.57
Enterprise Value ?
₹124 Cr
EV/EBITDA ?
18.31
PEG ?
0.17
Earnings Yield ?
5.2%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹47 Cr
OPM ?
14.5%
Profit after tax (TTM) ?
₹5 Cr
EPS (TTM) ?
₹10.01
ROCE ?
18.5%
ROE ?
12.3%
ROA ?
10.9%
Growth
Sales — latest qtr ?
₹9 Cr
PAT — latest qtr ?
₹1 Cr
YoY qtr sales growth ?
-22.5%
YoY qtr profit growth ?
-10.1%
Sales growth (3y) ?
300%
Sales growth (5y) ?
35%
Profit growth (3y) ?
136%
Profit growth (5y) ?
23%
Financial Health
Debt ?
₹2 Cr
Debt to Equity ?
0.05
Interest Coverage ?
15.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
71.15%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
58.9%
Return 6 months ?
67.9%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 0013018912121312129 -22.5% -22.3%
Operating Profit -0-0-1-0-001-0112221 -0.8% -31.1%
Other Income 00000001000100 -0.8% -7.2%
Interest 00000000000000 -64.5% -60.6%
Depreciation 00000000000000 +50.0% +28.6%
Profit Before Tax 0-0-00-0010122222 +1.4% -28.3%
Net Profit 0-0-010010111211 -10.1% +28.2%
EPS 0.10-0.08-1.211.620.790.921.670.561.821.882.373.741.321.69 -10.1% +28.0%
OPM % -60.7% -92.5% -121.2% -6.2% -273.3% 20.4% 11.5% -3.2% 10.2% 11.7% 12.0% 14.6% 16.9% 14.9% +27.4% -11.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹31 Cr ₹49 Cr ₹47 Cr +61.1%
Operating Profit ₹2 Cr ₹7 Cr ₹7 Cr +206.8%
OPM % 7.22% 13.75% 14.52% +90.4%
NPM % 6.34% 10.75% 11.13% +69.6%
Other Income ₹1 Cr ₹1 Cr ₹1 Cr -4.7%
Depreciation ₹0 Cr ₹0 Cr ₹0 Cr +52.9%
Interest ₹0 Cr ₹0 Cr ₹0 Cr +23.5%
EBIT ₹2 Cr ₹7 Cr ₹6 Cr +219.6%
PBT ₹3 Cr ₹8 Cr ₹8 Cr +136.2%
Tax — — ₹1 Cr —
Net Profit ₹2 Cr ₹5 Cr ₹5 Cr +173.2%
EPS ₹4.97 ₹9.31 ₹9.12 +87.3%
Material Cost — — ₹4 Cr —
Employee Cost — — ₹0 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 3.905.705.7011.09 +94.6%
Reserves 11.6222.3725.7931.02 +20.3%
Borrowings 0.009.2110.161.92 -81.1%
Other Liabilities 2.534.515.523.40 -38.4%
Total Liabilities 18.0541.7947.1747.43 +0.6%
Fixed Assets 5.7914.9515.5816.39 +5.2%
CWIP 0.000.000.000.00 —
Investments 0.000.000.000.00 —
Other Assets 12.2626.8431.5931.04 -1.7%
Total Assets 18.0541.7947.1747.43 +0.6%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -2.522.68-2.870.74 +125.8%
Cash from Investing Activity 3.351.520.630.08 -87.3%
Cash from Financing Activity 0.000.47-1.20-3.40 -183.3%
Net Cash Flow 0.834.67-3.43-2.58 +24.8%
Free Cash Flow -2.522.79-3.69-0.35 +90.5%
CFO/OP 175%-13,400%-75%11% +114.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 180.1381.7282.2270.02 -14.8%
Inventory Days 1,971.00149.98106.2086.11 -18.9%
Days Payable 87.6046.4939.4413.71 -65.2%
Cash Conversion Cycle 2,063.53185.21148.99142.42 -4.4%
Working Capital Days 2,360.65131.25138.28133.98 -3.1%
ROCE % -2.79%7.20%13.20%18.49% +40.1%

👥 Shareholding (latest 4 periods)

Metric Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 71.15%71.15%71.15%71.15% +0.0%
FIIs 0.00%0.00%0.00%0.18% —
Public 28.85%28.84%28.85%28.67% -0.6%
No. of Shareholders 3,0873,0382,9822,960 -0.7%

⚖️ Peer comparison

Industry: Medical Equipment & Supplies · 13 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 FISCHER Fischer Medical ₹33.50 2,293 85.2 367 24 12.3% 6.7% 178.6% 2051.4% 249.4% -24.3%
2 TARSONS Tarsons Products ₹330.00 1,756 157.9 441 11 27.0% 2.5% -66.3% -81.4% 20.7% -181.0%
3 DENTALKART Vasa Denticity ₹563.10 977 80.0 299 12 4.4% 4.0% 16.7% -28.5% 12.9% -2.9%
4 543916 Hemant Surgical ₹193.85 544 13.9 231 18 10.4% 7.8% — — 187.9% 160.0%
5 543363 Prevest Denpro ₹616.50 456 32.8 75 23 35.7% 29.9% 13.6% 17.6% 23.7% 24.8%
6 QMSMEDI QMS Medical ₹185.89 359 52.7 162 7 13.1% 4.1% 5.1% -47.9% 23.7% -0.8%
7 NURECA Nureca ₹331.55 331 75.9 153 4 2.7% 2.8% 34.0% 146.7% 18.0% 277.2%
8 530427 Choksi Asia ₹65.64 122 7.2 47 5 14.5% 11.1% 61.1% 173.2% -22.5% -10.1%
9 527005 Shree Pacetronix ₹168.25 55 19.2 21 3 24.8% 15.3% 28.7% 324.3% -8.3% 14.5%
10 544143 Royal Sense ₹139.00 47 24.7 38 3 12.8% 8.0% — — 2.5% -5.4%
11 533212 GKB Ophthalmics ₹104.90 32 17.6 150 6 7.0% 3.7% 36.8% 142.7% 2.3% 388.5%
12 531380 Centenial Surgical ₹110.90 27 — 56 -1 10.7% -2.6% 0.6% -38.1% 18.6% 1937.8%
13 542765 Transpact Enterprises ₹325.00 4 140.1 0 0 63.2% 47.4% — — 12.5% -20.0%
❓ Frequently asked questions
What was Choksi Asia Ltd's revenue in Q1 FY27?
Choksi Asia Ltd reported revenue of ₹9 crore for the quarter ended June 2026 (Q1 FY27), down 22.5% from ₹12 crore in the same quarter last year, and down 22.3% sequentially over the March 2026 quarter.
What was Choksi Asia Ltd's net profit in Q1 FY27?
Net profit fell 10.1% year-on-year to ₹1 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹1.69.
What is 530427's market capitalisation and P/E ratio?
At the current price of ₹235.20, 530427 has a market capitalisation of ₹122 crore and a trailing P/E of about 23.5.
Who owns Choksi Asia Ltd? (shareholding pattern)
As of Jun 2026, promoters held 71.15%, foreign institutional investors (FIIs) 0.18%, public shareholders 28.67% of Choksi Asia Ltd.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI